Zacks Investment Research lowered shares of TESARO, Inc. (NASDAQ:TSRO) from a hold rating to a sell rating in a report issued on Tuesday, October 17th.
According to Zacks, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. “
A number of other research analysts also recently issued reports on the company. ValuEngine upgraded TESARO from a sell rating to a hold rating in a report on Tuesday, August 1st. Gabelli assumed coverage on TESARO in a research report on Friday, July 7th. They issued a buy rating and a $175.00 price objective for the company. Credit Suisse Group set a $198.00 price objective on TESARO and gave the stock a buy rating in a research report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reissued a buy rating and issued a $199.00 price objective on shares of TESARO in a research report on Sunday, September 10th. Finally, BidaskClub raised TESARO from a strong sell rating to a sell rating in a research report on Wednesday, August 23rd. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. TESARO currently has a consensus rating of Hold and an average target price of $166.10.
TESARO (TSRO) traded up $1.59 on Tuesday, reaching $112.50. The company’s stock had a trading volume of 375,943 shares, compared to its average volume of 549,272. TESARO has a one year low of $106.64 and a one year high of $192.94. The company has a current ratio of 5.69, a quick ratio of 5.41 and a debt-to-equity ratio of 0.34.
TRADEMARK VIOLATION WARNING: This report was originally reported by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://baseballnewssource.com/markets/tesaro-inc-tsro-cut-to-sell-at-zacks-investment-research/1721919.html.
In related news, VP Grant C. Bogle sold 14,167 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James O. Armitage sold 10,000 shares of the stock in a transaction on Monday, September 18th. The shares were sold at an average price of $117.13, for a total value of $1,171,300.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $1,171,300. The disclosure for this sale can be found here. Insiders sold 35,692 shares of company stock worth $4,628,976 in the last three months. 34.60% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of TSRO. BlackRock Inc. grew its holdings in shares of TESARO by 4,504.8% during the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock worth $524,643,000 after purchasing an additional 3,335,611 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of TESARO during the second quarter worth about $100,301,000. PointState Capital LP purchased a new position in shares of TESARO during the second quarter worth about $85,971,000. Pictet Asset Management Ltd. grew its holdings in shares of TESARO by 58.1% during the third quarter. Pictet Asset Management Ltd. now owns 630,904 shares of the biopharmaceutical company’s stock worth $81,450,000 after purchasing an additional 231,799 shares during the last quarter. Finally, Pioneer Investment Management Inc. grew its holdings in shares of TESARO by 195.6% during the second quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock worth $44,441,000 after purchasing an additional 210,273 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with our FREE daily email newsletter.